Irinotecan and Anlotinib for Epithelioid Sarcoma

Withdrawn Peking University People's Hospital

NaSingle-groupOpen-labelTreatment

Summary

Epithelioid sarcoma is a rare soft tissue sarcoma characterized by SMARCB1/INI1 deficiency. Much attention has been paid to the selective EZH2 inhibitor tazemetostat, where other systemic treatments are generally ignored. To explore alternative treatment options, we studied the effects of irinotecan-based chemotherapy in a series of epithelioid sarcoma patients.

Timeline

Start: 2021-08-01
Primary completion: 2024-10-01
Completion: 2024-12-01

Outcome

Outcome not reported

Stopped: “Check the IRB again”

Publications

Xie L, Sun X, Xu J, Liang X, Liu K, Sun K, Yang R, Tang X, Guo W. The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma. BMC Cancer. 2024 Feb 3;24(1):172. doi: 10.1186/s12885-024-11921-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Catequentinib	Small molecule	12 mg	Oral
Subject	Irinotecan	Small molecule	50 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.4 mg/m2	—

Indications

No indication recorded.